← All countries · Eastern Mediterranean
99%
MCV1
2025 · WHO/UNICEF estimate
98%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
98%
HepB3
2025 · WHO/UNICEF estimate
826
Measles cases
2025 reported
482
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 97%2025 · WHO/UNICEF estimate | 96.8% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 98.1% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 98.1% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | 97.7% | C · weak | |
| MCV1First dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 98.7% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 98.6% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 99%2025 · WHO/UNICEF estimate | 98.7% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 99%2025 · WHO/UNICEF estimate | 99.6% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 98.1%2025 · Administrative (country-reported) | 98.1% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| RotaCRotavirus vaccine, complete series | 98%2025 · WHO/UNICEF estimate | 97.7% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | 96.4%2020 · Administrative (country-reported) | 96.4% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 62%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 47%2023 · WHO/UNICEF estimate | — | too few points | D · poor |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 8262025 | 23.9per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 622025 | 1.8per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 2462025 | 7.1per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 4822025 | 13.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 12025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Invasive meningococcal disease all countries · vaccine evidence | 3072025 | 8.9per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 792025 | 2.3per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (48 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | M6 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | <Y7 | Risk group(s) | DTP contrindicated |
| DTAPDTaP (acellular) vaccine | 5 | Y4-Y6 | General/routine | |
| DTAPHIBDTaP-Hib (acellular) vaccine | 4 | M18 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M18 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | M24 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11-Y12 | HPV for females only | The vaccine is indicated for any girls aged 9-26 Y to receive one dose and we use schoolbased vaccination to vaccinate grade 7 girls. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 50Y |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEASLESMeasles vaccine | 1 | M9 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M9 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y18 | Risk group(s) | Premarital and postnatal females |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +D30 | Risk group(s) | Premarital and postnatal females |
| MMRMMR (Measles, mumps and rubella) vaccine | 3 | Y4-Y6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 1 | M6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 2 | M12 | General/routine | |
| OPVOPV (Oral polio vaccine) | 3 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | Y4-Y6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Y18 | Risk group(s) | High risk groups |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M12 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y60 | Adults | 60Y and above |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women between 27-36 weeks | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y7 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M18 | General/routine | |
| VARICELLAVaricella vaccine | 2 | Y4-Y6 | General/routine | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y50 | Adults | 50 years and above |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2-M6 | Adults | 50 years and above |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.